Forming your phase III trial's data and safety monitoring board: A perspective on safety

Journal of Investigative Medicine

Volumn 52, Issue 7, 2004, Pages 453-458

  Wittes, Janet ^a  

^a University of Iowa   (United States)

Author keywords

Clinical trials; Data safety monitoring boards; Safety monitoring

Indexed keywords

CLINICAL TRIAL; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; REVIEW; SAFETY; ARTICLE; CONTROLLED STUDY; HUMAN; MEDICAL RESEARCH; PHASE 3 CLINICAL TRIAL;

EID: 11244299567     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1136/jim-52-07-37     Document Type: Review

References (11)

1. US Food and Drug Administration. Guidance for clinical trial sponsors: on the establishment and operation of clinical trial data monitoring committees - 2001. Available at: http://www.fda.gov/cber/guidelines.htm (accessed September 29, 2004).
2. National Institutes of Health. NIH policy for data and safety monitoring - 1998. Available at: http://grants.nih.gov/grants/guide/notice-files/not98-084. html (accessed September 29, 2004).
3. Steinbrook R. Improving protection for research subjects. N Engl J Med 2002;346:1425-30
4. National Institutes of Health. Clinical trial committee guide. Vol. 8 No. 8. Bethesda, MD: National Institutes of Health; 1979.
5. Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials. Chichester (UK): John Wiley And Sons; 2002.
6. National Institutes of Health. NIH Guide 23(11):March 18, 1994.
7. International Conference on Harmonisation. E9: statistical principles for clinical trials. Available at: http://www.ICH.org (accessed September 29, 2004).
8. Wittes J. Data safety monitoring boards: a brief introduction. Biopharm Rep 2000;8:1-7.
9. Meinert CL. Masked monitoring in clinical trials: blind stupidity? N Engl J Med 1998;338:1381-2.
10. Snappin S. Discussion. Biopharm Rep 2000;8:7-8.
11. Good I. The estimation of probabilities; an essay on modern Bayesian methods. Cambridge (MA): MIT Press; 1965.